Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin- piperaquine in adult patients with uncomplicated malaria: A multi-centre study in Indonesia

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Tjitra, Emiliana ^a   Hasugian, Armedy R ^a   Siswantoro, Hadjar ^a   Prasetyorini, Budi ^a   Ekowatiningsih, Riyanti ^a   Yusnita, Endah A ^a   Purnamasari, Telly ^a   Driyah, Srilaning ^a   Salwati, Ervi ^a   Nurhayati, ^a   Yuwarni, Eni ^a   Januar, Lidwina ^b   Labora, Joseph ^c   Wijayanto, Bambang ^d   Amansyah, Fajar ^e   Dedang, Tersila Ad ^f   Purnama, Asep ^g   Trihono, ^a  

^a NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^b Centre for Biomedical Research and Development   (Indonesia)

^c Marthen Indeys Army Hospital   (Indonesia)

^d Soedibjo Sardadi Navy Hospital   (Indonesia)

^e Bhayangkara Police Hospital   (Indonesia)

^f Kewapante Catholic Hospital   (Indonesia)

^g TC Hillers District Public Hospital   (Indonesia)

Author keywords

Artemisinin naphthoquine; Dihydroartemisinin piperaquine; Efficacy; Malaria; Safety

Indexed keywords

ANTIMALARIAL AGENT; ARCO; ARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUO COTECXIN; NAPHTHOQUINE; UNCLASSIFIED DRUG; ARTEMISININ DERIVATIVE; ARTEMISININ NAPHTHOQUINE COMBINATION; ARTEMISININ-NAPHTHOQUINE COMBINATION; DIHYDROARTEMISININ; NAPHTHOQUINONE; PIPERAQUINE; PROTOZOAL DNA; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEART PALPITATION; HOSPITALIZATION; HUMAN; INDONESIA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MICROSCOPY; MIXED INFECTION; MULTICENTER STUDY; MYALGIA; NAUSEA; PARASITE CLEARANCE; PARASITOLOGY; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SMEAR; SWEATING; TABLET; VOMITING; WORLD HEALTH ORGANIZATION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MALARIA; MIDDLE AGED; PARASITEMIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; DNA, PROTOZOAN; FEMALE; HUMANS; INDONESIA; MALARIA; MALE; MIDDLE AGED; NAPHTHOQUINONES; PARASITEMIA; POLYMERASE CHAIN REACTION; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860387805     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-153     Document Type: Article

References (35)

1. World Health Organization, World Malaria Report 2008. WHO/HTM/GMP/2008.1 WHO, Geneva 2008
2. World Health Organization, Antimalarial drug combination therapy WHO, Geneva 2001
3. Effects of artemisinin derivatives on malaria transmissibility. Price RN, Nosten F, Luxemburger C, Ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, Lancet 1996 347 1654 1658 10.1016/S0140-6736(96)91488-9 8642959 (Pubitemid 26177386)
4. Effects of artesunate-mefloquine combination on incidence ofPlasmodium falciparummalaria and mefloquine resistance in western Thailand: a prospective study. Nosten F, van Vugt M, Price RN, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, Lancet 2000 356 297 302 10.1016/S0140-6736(00)02505-8 11071185 (Pubitemid 30459588)
5. Evaluation of antimalaria drugs in Indonesia, 1981-1995. Tjitra E, Gunawan S, Laihad F, Marwoto H, Sulaksono S, Arjoso S, Richie TL, Manurung N, Bull Hlth Studies 1997 25 27 58
6. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistantPlasmodium falciparumandPlasmodium vivaxmalaria. Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PMP, Laihad F, Anstey NM, Tjitra E, Price RN, Clin Infect Dis 2007 44 1067 1074 10.1086/512677 17366451 (Pubitemid 46580274)
7. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN, Lancet 2007 369 757 765 10.1016/S0140-6736(07)60160-3 17336652 (Pubitemid 46335820)
8. Hundred one casesPlasmodium falciparumtreated with naphthoquine phosphate. Pang X, Wang G, Xing Q, Chinese J Parasitic Disease 1999 17 20 22
9. Clinical trial of co-naphthoquine in the treatment of falciparum malaria. Wang JY, Shan CQ, Fu D, Chin J Parasit Dis Con 2003 16 135 136
10. A randomized controlled study of napthoquine and artesunate in the treatment of falciparum malaria. Guo WZ, Zheng Q, Li G, Guo XB, Journal of Guangzhou University Traditional Chinese Medicine 2003 17 235 237
11. Naphthoquine phosphate and its combination with artemisinin. Wang JY, Cao W, Shan CQ, Zhang M, Li GF, Ding DB, Shi YL, Wu BA, AMMS China, Acta Trop 2004 89 375 381 10.1016/j.actatropica.2003.11.008 14744564 (Pubitemid 38117074)
12. World Health Organization, Guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108 WHO, Geneva 2006
13. Schulz KF, Grimes DA, The Lancet Handbook of Essential Concepts in Clinical Research. Main edition Elsevier, Edinburg, London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto 2006
14. World Health Organization, Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria WHO, Geneva 2003
15. World Health Organization, Methods and techniques for clinical trials on antimalarial drug efficacy. Genotyping to identify parasite populations. Informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization. 29-31 May 2007 WHO, Amsterdam, The Netherlands 2008
16. Modified intention to treat reporting in randomized controlled trials: systematic review. Abraha I, Montedori A, BMJ 2010 340 2697 Epub 2010/06/16 10.1136/bmj.c2697 20547685
17. Monitoring and Reporting Adverse Events. World Health Organization, Toxicity Grading Scale for Determining Severity of Adverse Events, 2003 http://icssc.org/documents/AE%20Manual%202003%20Appendices%20February-06- 2003%20final.pdf
18. Amodiaquine-artesunate versus amodiaquine for uncomplicatedPlasmodium falciparummalaria in African children: a randomised, multicentre trial. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WRJ, Lancet 2002 359 1365 1372 10.1016/S0140-6736(02)08348-4 11978332 (Pubitemid 34442375)
19. World Health Organization, The use of artemisinin and its derivatives as antimalarial drugs: report of a joint CTD/DMP/TDR Informal Consultation, WHO/MAL/98.1086 WHO, Geneva 1998
20. Benefits of using multiple first-line therapies. Boni MF, Smith DL, Laxminarayan R, Proc Natl Acad Sci USA 2008 105 14216 14221 10.1073/pnas. 0804628105 18780786
21. The search for effective and sustainable treatment forPlasmodium falciparummalaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. Watkins WM, Sibley CH, Hastings IM, AmJTrop Med Hyg 2005 72 163 173 (Pubitemid 41278901)
22. Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria. Tun T, Tint HS, Lin K, Kyaw TT, Myint MK, Khaing W, Tun ZW, Acta Trop 2009 111 275 278 10.1016/j.actatropica. 2009.05.007 19464245
23. Artemisinin-naphthoquine combination (ARCOTM) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Hombhanje FW, Linge D, Saweri A, Kuanch C, Jones R, Toraso S, Geita J, Masta A, Kevau I, Hiawalyer G, Sapuri M, Malar J 2009 8 196 10.1186/1475-2875-8-196 19671190
24. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Denis MB, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D, Clin Infect Dis 2002 35 1469 1476 10.1086/344647 12471565 (Pubitemid 36020689)
25. Dihydroartemisinin-piperaquine against multidrug-resistantPlasmodium falciparummalaria in Vietnam: randomized clinical trial. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, Dong THA, Tran TT, Stepniewska K, White NJ, Farrar J, Lancet 2004 363 18 22 10.1016/S0140-6736(03)15163-X 14723988 (Pubitemid 38076920)
26. Randomized, controlled dose-optimization studies of dihydroartemisinin- piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ, J Infect Dis 2004 190 1773 1782 10.1086/425015 15499533 (Pubitemid 39487822)
27. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria an open-label randomized comparison. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo APP, Naing AL, Nyo MY, Myint NZH, Imwong M, Ashley E, Lee SJ, White NJ, Lancet 2006 367 2075 2085 10.1016/S0140-6736(06)68931-9 16798391 (Pubitemid 43949291)
28. An open, randomized comparison of artesunate plus mefloquine vs dihydroartemisinin-piperaquine for the treatment of uncomplicatedPlasmodium falciparummalaria in the Lao Peoples Democratic Republic (Laos). Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends M, Keola S, Pongvongsa T, Phompida S, Phetsouvanh R, Stepniewska K, White NJ, Newton PN, Trop Med Int Health 2006 11 1157 1165 10.1111/j.1365-3156.2006.01671.x 16903879 (Pubitemid 44125705)
29. Changes in the peripheral blood eosinophil count in falciparum malaria. Davis TM, Ho M, Supanaranond W, Looareesuwan S, Pukrittayakamee S, White NJ, Acta Trop 1991 48 243 246 10.1016/0001-706X(91)90052-L 1671625
30. Eosinophilic response to falciparum malaria infections. Shanks GD, Wilairatanaporn C, Southeast Asian J Trop Med Public Health 1992 23 795 797 1298092
31. Pseudoeosinophilia associated with malaria infection determined in the Sysmex XE-2100 hematology analyzer. Huh J, Jung J, Yoon H, Chung W, Ann Hematol 2005 84 400 402 10.1007/s00277-004-0987-z 15616813 (Pubitemid 40823355)
32. Malaria detection with the Sysmex XE-2100 hematology analyzer using pseudoeosinophilia and abnormal WBC scattergram. Huh HJ, Oh GY, Huh JW, Chae SL, Ann Hematol 2008 87 755 759 10.1007/s00277-008-0486-8 18427808
33. Efficacy of naphthoquine, artemisinin and combination of the two drugs in the treatment of falciparum malaria. Wang JY, Sun ZW, Fu DD, Clin J Parasitic Dis 2003 21 131 133
34. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one dayversusartemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte dIvoire. Toure OA, Penali LK, Yapi JD, Ako BA, Toure W, Djerea K, Gomez GO, Makaila O, Malar J 2009 8 148 10.1186/1475-2875-8-148 19575797
35. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Benyamin J, Moore B, Lee ST, Senn M, Griffin S, Lautu D, Salman S, Siba P, Mueller I, Davis TM, Antimicrob Agents Chemother 2012 56 2465 2471 10.1128/AAC.06248-11 22330921